glp-1 cardiovascular outcomes 2025 news studies add to growing body of evidence demonstrating significant benefit on GLP-1 Agonists in Cardiovascular Diseases:

The trainer called him lazy and said he needed an attitude adjustment

This study is very helpful to convince both clinicians and patients that maybe it is worth continuing a medication even without the weight loss. Study to examine whether Ozempic can reduce the risk of blood cancer When generic versions of weight-loss drugs arrive, public plans should cover them, experts say MASH is the more serious form of metabolic dysfunction-associated steatotic liver disease, or MASLD, which affects about 25 per cent of the adult population in Canada

The safest goal is steady fat loss with muscle preservation and long-term maintenance planning

hol+: Where Fertility Support Meets Root-Cause Care Fertility is personal, emotional, and deeply physicaland it deserves a whole-body approach

Working closely and communicating effectively with your provider is necessary for your treatment success, she tells us